^
    Back
    Association details:
    Biomarker:SRC mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood

    Published date:
    07/17/2020
    Excerpt:
    The only one patient with SRC mutation had a PFS of 4.5 months.
    DOI:
    10.1002/cam4.3319